+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics



Cost-effectiveness of hepatitis A/B vaccine versus hepatitis B vaccine in public sexually transmitted disease clinics



Sexually Transmitted Diseases 30(11): 859-865



Many patients seen at U.S. sexually transmitted disease (STD) clinics are offered hepatitis B vaccination. Substituting hepatitis A/B vaccine would provide additional protection but increase costs. The goal was to estimate the cost effectiveness of hepatitis A/B versus B vaccination for 1,000,000 public STD clinic attenders. A Markov model of hepatitis A outcomes was developed using published literature, U.S. government databases, and expert panel opinion. Added vaccination costs were compared with savings from reduced hepatitis A treatment. Net costs were compared with life-years saved and quality-adjusted life-years (QALYs) gained. Substituting hepatitis A/B vaccine would prevent 2263 overt hepatitis A infections, 292 hospitalizations, 8 premature deaths, and the loss of 281 QALYs. Net health system costs would be $20,892 per life-year saved, or $13,397 per QALY gained. Substituting hepatitis A/B for hepatitis B vaccine would reduce morbidity and mortality in a cost-effective manner.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011907303

Download citation: RISBibTeXText

PMID: 14603096

DOI: 10.1097/01.olq.0000086601.18907.47


Related references

Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States. Infection Control and Hospital Epidemiology 25(7): 563-569, 2004

The cost-effectiveness of using hepatitis A/B combined vaccine versus hepatitis B vaccine alone for high-risk heterosexuals. Vaccine 26(42): 5331-5333, 2008

A cost-effectiveness analysis of interventions to increase repeat testing in patients treated for gonorrhea or chlamydia at public sexually transmitted disease clinics. Sexually Transmitted Diseases 32(9): 542-549, 2005

Syphilis Time to Treatment at Publicly Funded Sexually Transmitted Disease Clinics Versus Non-Sexually Transmitted Disease Clinics--Maricopa and Pima Counties, Arizona, 2009-2012. Sexually Transmitted Diseases 43(1): 30-33, 2016

Supplement 1. An Overview of the Clinical Development of Hepatitis A Vaccine || Administration of Hepatitis A Vaccine to a Military Population by Needle and Jet Injector and with Hepatitis B Vaccine. Journal of Infectious Diseases 171: S53-S60, 1995

Cost-effectiveness analysis of the universal use of hepatitis A vaccine in patients with chronic hepatitis C. Gastroenterology 118(4 Suppl 2 Part 1): AGA A679, 2000

Hepatitis B vaccine and hepatitis B markers: cost effectiveness of screening prehospital personnel. American Journal of Emergency Medicine 5(3): 205-206, 1987

Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection. Vaccine 21(25-26): 3556-3564, 8 September, 2003

Hepatitis B Vaccination in Sexually Transmitted Disease (Std) Clinics. Sex Transm Dis 28(3): 148-152, 2001

Prophylaxis of viral hepatitis: transfusion transmitted disease and the hepatitis B vaccine. Progress in Clinical and Biological Research 143: 357-367, 1983

The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: Is one dose sufficient?. Human Vaccines and Immunotherapeutics 12(11): 2765-2771, 2016

Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20(5): 488-494, 1999

Prevention of hepatitis b by immunization of patients in sexually transmitted disease srd clinics. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 264, 1992

Hepatitis B vaccination in sexually transmitted disease (STD) clinics: a survey of STD programs. Sexually Transmitted Diseases 28(3): 148-152, 2001

Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S. Public Health Reports 123(4): 504-513, 2008